Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 beat, “strong” 2025 guidance and deleverage targets will continue to sustain the stock momentum, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX: